By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pacific Biosciences today reported fourth-quarter revenues of $12.4 million, beating analysts' consensus estimate of $10.4 million.

The Menlo Park, Calif.-based sequencing technology firm said that it delivered and installed 17 instruments and had six bookings during the quarter ended Dec. 31. As of the end of the year, the company had a backlog of 16 PacBio RS instruments, which represent around $11 million in revenue.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rob Knight writes at Scientific American that microbiome studies are about to break out of the laboratory.

Harold Varmus, the director of the National Cancer Institute, has announced that he is stepping down after nearly five years.

In Nature this week: omic analysis of permafrost microbes, hookworm genome, and more.

Biologists turn to environmental DNA sampling to determine whether elusive or invasive species are shedding DNA in a given area.